MX2009011512A - Nuevos compuestos peptidos ciclicos. - Google Patents

Nuevos compuestos peptidos ciclicos.

Info

Publication number
MX2009011512A
MX2009011512A MX2009011512A MX2009011512A MX2009011512A MX 2009011512 A MX2009011512 A MX 2009011512A MX 2009011512 A MX2009011512 A MX 2009011512A MX 2009011512 A MX2009011512 A MX 2009011512A MX 2009011512 A MX2009011512 A MX 2009011512A
Authority
MX
Mexico
Prior art keywords
cyclic peptide
new cyclic
hepatitis
peptide compounds
virus
Prior art date
Application number
MX2009011512A
Other languages
English (en)
Inventor
Takuya Makino
Toshio Yamanaka
Hidenori Ohki
Junya Ishida
Ayako Toda
Yu Harayama
Shingeki Kunikawa
Hiroaki Mizuno
Hiroaki Ohtake
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007902312A external-priority patent/AU2007902312A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2009011512A publication Critical patent/MX2009011512A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un nuevo compuesto péptido cíclico o una sal de él, que tiene actividades contra el virus de la hepatitis C basadas en la actividad inhibidora contra la replicación de ARN del replicón del virus de la hepatitis C, a un proceso para su preparación, a una composición farmacéutica que lo contiene, y a un método para el tratamiento profiláctico y/o terapéutico de la hepatitis C en un ser humano o en un animal.
MX2009011512A 2007-05-02 2008-04-25 Nuevos compuestos peptidos ciclicos. MX2009011512A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007902312A AU2007902312A0 (en) 2007-05-02 New Cyclic Peptide Compounds
PCT/JP2008/058456 WO2008139986A1 (en) 2007-05-02 2008-04-25 New cyclic peptide compounds

Publications (1)

Publication Number Publication Date
MX2009011512A true MX2009011512A (es) 2009-11-12

Family

ID=39671779

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011512A MX2009011512A (es) 2007-05-02 2008-04-25 Nuevos compuestos peptidos ciclicos.

Country Status (14)

Country Link
US (1) US8603975B2 (es)
EP (2) EP2455098A1 (es)
JP (1) JP5459545B2 (es)
KR (1) KR20100017547A (es)
CN (1) CN101687012A (es)
AU (1) AU2008250254B2 (es)
BR (1) BRPI0810203A2 (es)
CA (1) CA2684557A1 (es)
ES (1) ES2396170T3 (es)
IL (1) IL201485A0 (es)
MX (1) MX2009011512A (es)
RU (1) RU2436795C2 (es)
TW (1) TW200911839A (es)
WO (1) WO2008139986A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010035722A1 (ja) * 2008-09-24 2010-04-01 アステラス製薬株式会社 ペプチド化合物およびその製造方法
WO2010088573A1 (en) * 2009-01-30 2010-08-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
EP2900684A2 (en) 2012-09-29 2015-08-05 Novartis AG Cyclic peptides and use as medicines
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
JP2016538317A (ja) 2013-08-26 2016-12-08 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎を防止または治療するための新規シクロスポリン類似体
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
CN112661808B (zh) * 2020-12-23 2022-05-27 浙江大学 一种酯肽类化合物及其制备方法和应用
WO2024206136A1 (en) * 2023-03-24 2024-10-03 Gilead Sciences, Inc. Process for preparing bulevirtide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271267A (ja) 1991-04-23 1993-10-19 Fujisawa Pharmaceut Co Ltd Ｆｒ９０１４５９物質、その製法及び用途
EP1091975B1 (fr) 1998-07-01 2005-12-14 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
EP1372695A2 (en) 2000-10-19 2004-01-02 Fujisawa Pharmaceutical Co., Ltd. Cell damage inhibitor
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
JP2007015926A (ja) * 2003-10-06 2007-01-25 Fujisawa Pharmaceut Co Ltd Ｃ型肝炎治療剤
KR101309409B1 (ko) 2004-10-01 2013-09-23 싸이넥시스, 인크. Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체
SG139750A1 (en) 2004-10-01 2008-02-29 Debiopharm Sa Ch Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3- [etval]4-cyclosporin
DE602005010607D1 (de) * 2004-11-22 2008-12-04 Astellas Pharma Inc Zyklosporinanalog
US7872097B2 (en) * 2005-10-26 2011-01-18 Astellas Pharma Inc. Cyclic peptide compounds

Also Published As

Publication number Publication date
EP2455098A1 (en) 2012-05-23
AU2008250254B2 (en) 2012-08-16
EP2150269B1 (en) 2012-11-21
US8603975B2 (en) 2013-12-10
JP5459545B2 (ja) 2014-04-02
CN101687012A (zh) 2010-03-31
RU2436795C2 (ru) 2011-12-20
ES2396170T3 (es) 2013-02-19
JP2010526024A (ja) 2010-07-29
EP2150269A1 (en) 2010-02-10
KR20100017547A (ko) 2010-02-16
RU2009144538A (ru) 2011-06-10
IL201485A0 (en) 2010-05-31
TW200911839A (en) 2009-03-16
WO2008139986A1 (en) 2008-11-20
CA2684557A1 (en) 2008-11-20
US20100120672A1 (en) 2010-05-13
AU2008250254A1 (en) 2008-11-20
BRPI0810203A2 (pt) 2014-10-14

Similar Documents

Publication Publication Date Title
MX2009011512A (es) Nuevos compuestos peptidos ciclicos.
TW200732351A (en) New cyclic peptide compounds
MY202109A (en) Viral replication inhibitors
WO2012027712A3 (en) Potent and selective inhibitors of hepatitis c virus
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
EA201201235A1 (ru) Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv
IL196815A0 (en) Hepatitis c virus inhibitors
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
HK1123733A1 (en) Viral hepatitis treatment
IL207468A (en) HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections
TN2012000214A1 (en) Hepatitis c virus inhibitors
TW200606162A (en) Pyrazolopyridine derivatives
MY152971A (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
MY194294A (en) Novel viral replication inhibitors
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
MX337936B (es) Compuestos inhibidores del virus de la hepatitis c.
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
BR112013028679A2 (pt) inibidores do vírus da hepatite c
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
WO2008069917A3 (en) Novel cyclic peptides
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
TW200612922A (en) Inhibitors of hsp90
DE112004000961D2 (de) Verwendung von Wirksubstanzen zur Vorbeugung oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal